Combining basal insulin analogs with glucagon-like peptide-1 mimetics

Diabetes Technology and Therapeutics

Volumn 13, Issue 9, 2011, Pages 873-881

  Perfetti, Riccardo ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; CJC 1134 PC; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SHORT ACTING DRUG; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; CONTINUOUS INFUSION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; WEIGHT GAIN;

EID: 80052067058     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0250     Document Type: Article

References (41)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32: 193-203.
2. Blickle JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A: Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009;11:379-386.
3. Hirsch IB, Yuan H, Campaigne BN, Tan MH: Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract 2009;15: 343-348.
4. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254-259. (Pubitemid 40170922)
5. Swinnen SG, Snoek FJ, Dain MP, DeVries JH, Hoekstra JB, Holleman F: Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther 2009;11:739-743.
6. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vä-hätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Leh-tonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabe-tologia 2006;49:442-451. (Pubitemid 43277866)
7. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE: A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 2004;328:274-280. (Pubitemid 39518531)
8. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E: A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23: 736-742. (Pubitemid 44366071)
9. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747.
10. Massi Benedetti M, Humburg E, Dressler A, Ziemen M: A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35: 189-196. (Pubitemid 36577862)
11. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086. (Pubitemid 37339502)
12. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636. (Pubitemid 32888839)
13. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30:263-269. (Pubitemid 46198328)
14. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens DR: Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hy-perglycaemia and HbA(1c) in subjects with Type 2 diabetes. Diabet Med 2009;26:974-980.
15. Owens DR: Adding a single dose of insulin glulisine to basal insulin glargine plus oral antihyperglycemic drug therapy improves glycemic control in type 2 diabetes: a 6-month proof-of-concept study [abstract]. Diabetes 2009;58: A122.
16. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S: The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340:b5444. doi: 10.1136/bmj.b5444.
17. Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
18. Ebert R, Creutzfeldt W: Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 1987;3:1-26. (Pubitemid 17002806)
19. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304. (Pubitemid 17156636)
20. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994;17:1039-1044. (Pubitemid 24268617)
21. Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88:220-224. (Pubitemid 36115169)
22. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-19655. (Pubitemid 23270754)
23. Datapharm Communications: Summary of Product Characteristics: Byetta 5 micrograms solution for injection, pre-filled pen. Byetta 10 micrograms solution for injection, prefilled pen. www.medicines.org.uk/emc/medicine/19257# PHARMACOLOGICAL-PROPS 2010 (accessed December 21, 2010).
24. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM: Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009;18:359-367.
25. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tol-erability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202. (Pubitemid 34208381)
26. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacoki-netics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25:1398-1404. (Pubitemid 41071152)
27. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ: An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011 Jan 5. doi: 10.1111/j.1463-1326.2011.01357.x. [Epub ahead of print].
28. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS: Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307:490-496. (Pubitemid 37310661)
29. Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH: Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin 2008;24:1395-1397. (Pubitemid 351741572)
30. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
31. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089. (Pubitemid 36877476)
32. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C: Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509-1515.
33. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J: Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-112.
34. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM: Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687-694.
35. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA: Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-292.
36. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mo-hanty P, Dandona P: Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-450.
37. Yoon NM, Cavaghan MK, Brunelle RL, Roach P: Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-1523.
38. Hirsch I, Silberman C, Calingaert B: Patient factors associated with GLP-1 analog use with and without insulin in type 2 diabetes (T2D): results from a large cohort analysis [abstract]. Diabetes 2010;59:601-P.
39. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458-463. (Pubitemid 41103336)
40. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ: Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-1483. (Pubitemid 41368581)
41. Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A: Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:604-612.